beta blockers and glp-1 for Weight Loss Diabetes Cardiovascular Protection with a Long-Acting

Introduction Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are key therapies for type 2 diabetes and obesity, regulating blood glucose by mimicking endogenous GLP-1

The bigger message is that these agents are pushing us toward a more integrated cardiometabolic model of care, in which obesity, heart failure, kidney disease, liver disease, and vascular risk are treated as connected biology rather than asseparate silos.

This increasing trend not only places a considerable burden on healthcare systems but also significantly affects the physical and psychological well-being of patients

This podcast is for informational purposes only and is not intended to replace professional medical advice.If you have a question for Dr